Biopharmaceutical company Gilead Sciences Inc (Nasdaq: GILD) on Monday reported real-world results from the BICSTaR study that reinforces the use of Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) as a generally well tolerated and efficacious regimen regardless of prior treatment and comorbidity status in people with HIV.
This latest five-year data from two Phase 3 studies (Study 1489 and Study 1490) provides evidence of the long-term safety and efficacy profile of Biktarvy in patients who switch from a dolutegravir-containing regimen.
Gilead presented new real-world data from the 24-month BICSTaR follow-up analysis which evaluated the effectiveness and safety of Biktarvy in clinical practice across nine countries. This analysis included follow-up during the COVID-19 pandemic and considered age, race, sex, adherence and late diagnosis in the population group.
The company stated that trial participants who initiated treatment with Biktarvy experienced high viral suppression (HIV-1 RNA
Seres Therapeutics provides business updates and reports Q2 2023 financial results
JanOne names new interim president of JanOne Biotech subsidiary
Estrella Biopharma and TradeUP Acquisition receives US FDA approval for EB103 IND application